| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
LysoPC(20:4) does not have a classical pharmacological target like an enzyme or receptor; it is an endogenous lipid molecule involved in lipid metabolism and cell signaling. Its primary role is as a precursor for the synthesis of lysophosphatidic acid (LPA) via the action of autotaxin (ENPP2), a lysophospholipase D. LPA is a potent bioactive lipid that signals through six G protein-coupled receptors (LPAR1-6) to regulate cell proliferation, migration, and survival. LysoPC(20:4) can also directly modulate immune cell function and inflammation. Decreased levels of LysoPC(20:4) in serum are associated with increased cancer risk, suggesting that it may have a protective role. The compound operates within the lysophospholipid and LPA signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, LysoPC(20:4) has been shown to affect cancer cell behavior. Treatment of cancer cell lines (e.g., ovarian, colon, breast) with LysoPC(20:4) at concentrations of 1-50 uM for 24-72 hours can influence cell proliferation, migration, and invasion, with effects that vary by cell type. It is converted to LPA by autotaxin, and LPA then activates LPARs, promoting cell migration and survival in many cancer types. However, LysoPC(20:4) itself can also induce apoptosis in some cell lines at higher concentrations (50-100 uM). The compound is not a typical inhibitor or activator with a defined IC50; its activity is context-dependent. In lipidomic studies, LysoPC(20:4) levels are measured as a biomarker rather than used as an exogenous treatment. For research use only.
|
| ln Vivo |
In vivo, LysoPC(20:4) has been studied as a biomarker in tumor-bearing mice. In xenograft models (e.g., colon cancer), serum LysoPC(20:4) levels decrease in tumor-bearing mice compared to controls, though the reduction is not always significant. The negative correlation between LysoPC(20:4) level and cancer risk suggests that lower levels may be associated with more aggressive tumors. This compound is not used as a therapeutic agent in vivo; it is typically measured as an endogenous metabolite in serum or plasma for diagnostic or prognostic purposes. In some research contexts, LysoPC(20:4) may be administered to animals to study its metabolic fate or its role in LPA signaling, but such studies are limited. For research use only.
|
| Enzyme Assay |
Not applicable for enzyme/receptor binding assays. LysoPC(20:4) is an endogenous lipid metabolite, and its concentration is typically measured rather than its activity. For non-cellular characterization, a standard LC-MS/MS protocol is used: dissolve LysoPC(20:4) in methanol or chloroform:methanol (1:1) to prepare 1 mg/mL stock. Dilute to working concentrations (0.1-100 ng/mL) in mobile phase (e.g., methanol:water:formic acid, 80:20:0.1). Inject into LC-MS/MS with C18 column (2.1×100 mm, 1.7 um). Mobile phase A: water + 0.1% formic acid, B: methanol + 0.1% formic acid. Gradient: 50% B to 98% B over 5 min. Flow rate 0.3 mL/min. MRM transitions: m/z 544.3 → 184.1 (for phosphocholine head group) and m/z 544.3 → 361.4 (for arachidonoyl fragment). Quantitate by external calibration curve. Retention time ~4-5 min. No enzyme inhibition assays are performed.
|
| Cell Assay |
For in vitro cell assays, LysoPC(20:4) is not typically used as a treatment because it is an endogenous metabolite. However, for mechanistic studies, cells (e.g., ovarian cancer cells, macrophages) can be cultured in lipid-free medium and treated with LysoPC(20:4) at 1-50 uM for 6-48 h. Prepare 10 mM stock in ethanol or DMSO (store at -20degC); dilute in culture medium (final DMSO/ethanol ≤0.1%). For proliferation assays, seed cells in 96-well plates (5×103 cells/well), treat with LysoPC(20:4) for 48 h, and measure viability by MTT. For migration assays, use transwell chambers (8 um pore size), add LysoPC(20:4) to lower chamber as a chemoattractant (1-20 uM), seed cells in upper chamber, and count migrated cells after 12-24 h. For LPA production measurement, treat cells with LysoPC(20:4) in the presence of autotaxin (0.1-1 ug/mL), collect supernatant, and measure LPA by LC-MS/MS. Vehicle control (0.1% ethanol or DMSO). Positive control: LPA (1 uM) for migration assays. All experiments in triplicate.
|
| Animal Protocol |
For in vivo studies, LysoPC(20:4) is not administered as a drug; rather, its endogenous levels are measured in animal models of disease. A typical study: female BALB/c nude mice (6-8 weeks, n=10/group) are injected subcutaneously with cancer cells (e.g., HCT116 colon cancer cells, 5×10⁶ in Matrigel). Blood is collected by cardiac puncture at endpoint (when tumors reach ~1000 mm3). Serum is separated, proteins precipitated with ice-cold methanol, and supernatants analyzed by LC-MS/MS as described in non-cellular section. LysoPC(20:4) levels are compared between tumor-bearing and sham control mice. The compound can also be administered intravenously to trace its metabolism: inject 1-10 mg/kg LysoPC(20:4) (formulated in 10% DMSO/40% PEG300/5% Tween 80/45% saline) into tail vein of rats or mice, collect blood at time points 0, 5, 15, 30, 60, 120 min, and measure LysoPC(20:4) and LPA by LC-MS/MS. This provides information on the conversion rate of LysoPC to LPA by autotaxin. No therapeutic efficacy studies are performed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of LysoPC(20:4) as an exogenous compound are not well-characterized because it is an endogenous metabolite. If administered intravenously in rodents at 1-10 mg/kg, the compound is rapidly taken up by tissues and metabolized. Plasma half-life (t½) is very short, likely <5 minutes, due to rapid hydrolysis by lysophospholipases and conversion to LPA by autotaxin. Volume of distribution (Vd) is moderate (~0.5-1 L/kg). Clearance (CL) is high, mostly via hepatic metabolism. Oral bioavailability is negligible due to first-pass metabolism. Endogenous plasma levels in mice range from 1-10 uM depending on diet and disease state. For storage, the compound is supplied as a powder or in chloroform solution. Lyophilized powder should be stored at -20degC under inert atmosphere, protected from light. Solutions in organic solvents should be stored at -80degC in glass vials to avoid degradation. Do not store in plastic, as phospholipids adsorb to plastic surfaces.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are available for LysoPC(20:4) as an exogenous compound because it is an endogenous metabolite. At physiological concentrations (1-10 uM), it is non-toxic. At higher concentrations (>50 uM), it can induce cell death in some cell types due to lysophospholipid-induced membrane disruption and oxidative stress. For research use, standard laboratory safety precautions for handling lipid standards should be followed: avoid inhalation, ingestion, skin/eye contact; use PPE (gloves, lab coat, safety goggles); work in a chemical fume hood. Not for human use. Dispose of waste according to local regulations. The compound may be harmful to aquatic life with long-lasting effects.
|
| References |
|
| Additional Infomation |
CAS: 60701-99-7. Molecular formula: C28H50NO7P, molecular weight: 543.67. IUPAC name: [(2R)-2-hydroxy-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate. Synonyms: 1-Arachidonoyl-sn-glycero-3-phosphocholine. Appearance: solid powder or oil. Purity typically >98% by HPLC. Solubility: soluble in chloroform, methanol, ethanol; may form micelles in water. Storage: -20degC, inert atmosphere, protect from light. Research areas: metabolomics, cancer biomarker studies, LPA signaling. Not for human use. For research only.
|
| Molecular Formula |
C28H50NO7P
|
|---|---|
| Molecular Weight |
543.67
|
| Exact Mass |
543.332
|
| CAS # |
60701-99-7
|
| PubChem CID |
24779476
|
| Appearance |
White to yellow Oil
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
37
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)O
|
| InChi Key |
LAXQYRRMGGEGOH-JXRLJXCWSA-N
|
| InChi Code |
InChI=1S/C28H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-28(31)34-25-27(30)26-36-37(32,33)35-24-23-29(2,3)4/h9-10,12-13,15-16,18-19,27,30H,5-8,11,14,17,20-26H2,1-4H3/b10-9-,13-12-,16-15-,19-18-/t27-/m1/s1
|
| Chemical Name |
[(2R)-2-hydroxy-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
|
| Synonyms |
1-Arachidonoyl-sn-glycero-3-phosphocholine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8394 mL | 9.1968 mL | 18.3935 mL | |
| 5 mM | 0.3679 mL | 1.8394 mL | 3.6787 mL | |
| 10 mM | 0.1839 mL | 0.9197 mL | 1.8394 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
